Company news
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news
Atara Biotherapeutics, Inc. news releases on 6ix. Latest, Nov 8, 2023: Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical…
Press releases — page 2
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
November 7, 2023
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
October 31, 2023
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 18, 2023
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
August 30, 2023
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
August 7, 2023
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
July 31, 2023
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 30, 2023
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 6, 2023
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
June 4, 2023
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
May 7, 2023
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
April 30, 2023
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 7, 2023
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
February 5, 2023
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2023
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2023
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
December 19, 2022
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 18, 2022
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
November 7, 2022
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 31, 2022
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
October 13, 2022
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
September 27, 2022
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
August 7, 2022
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
July 11, 2022
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
July 5, 2022
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
June 3, 2022
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
May 18, 2022
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
May 4, 2022
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
April 4, 2022
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
April 3, 2022
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 3, 2022
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
February 27, 2022
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
February 17, 2022
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 16, 2022
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
January 25, 2022
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
January 5, 2022
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
December 12, 2021
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
December 8, 2021
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
November 29, 2021
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
November 3, 2021
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
October 27, 2021
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
October 3, 2021
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
September 26, 2021
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
August 8, 2021
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
August 8, 2021
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
June 6, 2021
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
May 9, 2021
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
May 3, 2021
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
February 28, 2021
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
February 17, 2021
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
January 3, 2021